Researchers at Oregon State University have announced that new therapy that stops the progression of ALS. The therapy is based on using Copper-ASTM, a compound that delivers copper specifically to cells with damages mitochondria. Full article
Read the latest news from the ALS Association's monthly newsletter May 2023 Local Newsletter: Learn about ALS National Awareness Month and the recent approval of the FDA for tofersen, a new gene-based therapy.April 2023 Local Newsletter: Announcements on spring events including the Mankato Walk to Defeat ALS, the Super Hero dash and so much more.April 2023 National Newsletter: Learn about accelerated approval of Tofersen and the path forward for PridopidineMarch 2023 Newsletter: New priorities announced for federal and state policies and advocation for medicare coverage for power seats in wheelchairsFebruary 2023 Newsletter: Update on key achievements achieved in 2022 [...]
The FDA advisory committee recently approved the use of AMX0035 for the treatment of ALS. Presented with the robustness of new evidence, the committee reversed their March 2022 vote overwhelming by a 7-2 vote. The ALS Association has publicly thanked both the FDA advisory committee and the entire ALS community for their hard work and advocacy. Read Full Article
AMX0035, developed by Amylyx Pharma out of Cambridge, is the first ALS treatment to come out of FDA Phase II trials that has been shown to slow or halt the progression of ALS as well as passing other criteria such as efficacy and limited side effects. The Michelle Gargaro Foundation is committed to providing assistance in any way they can to securing approval of AMX0035 with the FDA. We have pledged up to $5,000.00 towards the FDA approval of the use of AMX0035 for ALS patients. Please research AMX0035 on our website, or on the internet and support the effort. [...]
Earlier this month, our foundation made two donations to the local ALS Association chapter. A donation of $2,000.00 in honor of Michelle’s memory was made to the chapter in conjunction with their annual walk to defeat ALS. We asked that the donation be targeted to areas of research directed at finding meaningful treatments and/or cures for ALS. Our foundation made an additional donation of $1,000.00 to the local ALS chapter to be put towards providing support to ALS caregivers in their care of loved ones affected by ALS.
Amylyx Pharmaceuticals will have an FDA advisory committee to review a new drug application for AMX0035 for the treatment of ALS. For more details on the committee, see the full article in the AMYLX press release.
Perspective article from Stat on why the FDA should lead the way in ALS treatment
Learn about how the FDA has granted fast track to the approval of the APB-102 Gene Therapy in the article in the ALS News Today.
For a full understanding of the role and leadership of the ALS Association's Vision and Mission read this summary pdf
The ALS association sets its priorities and strategic to make ALS livable by 2030. Read full article.